RT Journal Article
T1 Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
A1 de Pablo, E
A1 O'Connell, Peter
A1 Fernández García, Raquel
A1 Marchand, Sandrine
A1 Chauzy, A.
A1 Tewes, F
A1 Dea Ayuela, María Auxiliadora
A1 Kumar, D.
A1 Bolas Fernández, Francisco
A1 Ballesteros Papantonakis, María De La Paloma
A1 Torrado Durán, Juan José
A1 Healy, Anne Marie
A1 Serrano López, Dolores Remedios
AB The incidence of fungal pulmonary infections is known to be on the increase, and yet there is an alarming gap in terms of marketed antifungal therapies that are available for pulmonary administration. Amphotericin B (AmB) is a highly efficient broad-spectrum antifungal only marketed as an intravenous formulation. Based on the lack of effective antifungal and antiparasitic pulmonary treatments, the aim of this study was to develop a carbohydrate-based AmB dry powder inhaler (DPI) formulation, prepared by spray drying. Amorphous AmB microparticles  were developed by combining 39.7% AmB with 39.7% γ-cyclodextrin, 8.1% mannose and 12.5% leucine. An increase in the mannose concentration from 8.1 to 29.8%, led to partial drug crystallisation. Both formulations showed good in vitro lung deposition characteristics (80% FPF< 5 µm and MMAD < 3 µm) at different air flow rates (60 and 30 L/min) when used with a DPI, but also during nebulisation upon reconstitution in water.
PB Elsevier
SN 0378-5173
YR 2023
FD 2023-03-25
LK https://hdl.handle.net/20.500.14352/73046
UL https://hdl.handle.net/20.500.14352/73046
LA eng
NO Ministerio de Ciencia e Innovacion de España
NO Science Foundation Ireland
DS Docta Complutense
RD 6 abr 2025